Tampa, Fla. (Feb. 22, 2011) — Transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) has been found to “significantly accelerate” wound closure in diabetic mouse models, said a team of Korean researchers publishing …
Laboratory culture (in vitro) studies examining the activity of human umbilical cord blood cells (HUCB) on experimental models of central nervous system aging, injury and disease, have shown that HUCBs provide a ‘trophic effect’ (nutritional effect)…
Human umbilical cord blood cells (HUCB) used to treat cultured rat brain cells (astrocytes) deprived of oxygen appear to protect astrocytes from cell death after stroke-like damage, reports a team of researchers from the University of South Florida …
Stem cells derived from human umbilical cord blood (HUCB) migrate to damaged areas in the brain and spinal cord caused by disease or injury and provide some therapeutic benefit, two new animal studies by researchers at the University of South Florida Center of Excellence for Aging and Brain Repair found. Both studies, conducted in collaboration with Saneron CCEL Therapeutics, Inc., appear in the the latest issue of the Journal of Hematotherapy & Stem Cell Research published today.
The cushioning material or matrix within the umbilical cord known as Wharton’s jelly is a rich and readily available source of primitive stem cells, according to findings by a research team at Kansas State University. Animal and human umbilical cord matrix cells exhibit the tell-tale characteristics of all stem cells, the capacity to self-renew and to differentiate into multiple cell types. The cells — called cord matrix stem cells to distinguish them from cord blood cells — can be obtained in a non-invasive manner from an abundant source of tissue that is typically discarded.